IL189329A - The vaccine against dengue fever virus infection has been used and used - Google Patents

The vaccine against dengue fever virus infection has been used and used

Info

Publication number
IL189329A
IL189329A IL189329A IL18932908A IL189329A IL 189329 A IL189329 A IL 189329A IL 189329 A IL189329 A IL 189329A IL 18932908 A IL18932908 A IL 18932908A IL 189329 A IL189329 A IL 189329A
Authority
IL
Israel
Prior art keywords
kit
same
virus infection
dengue virus
vaccination against
Prior art date
Application number
IL189329A
Other languages
English (en)
Hebrew (he)
Other versions
IL189329A0 (en
Original Assignee
Sanofi Pasteur Biologics Llc
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics Llc, Sanofi Pasteur filed Critical Sanofi Pasteur Biologics Llc
Publication of IL189329A0 publication Critical patent/IL189329A0/en
Publication of IL189329A publication Critical patent/IL189329A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL189329A 2005-08-10 2008-02-06 The vaccine against dengue fever virus infection has been used and used IL189329A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70703805P 2005-08-10 2005-08-10
US71944805P 2005-09-22 2005-09-22
PCT/US2006/030846 WO2007021672A2 (en) 2005-08-10 2006-08-09 Vaccination against dengue virus infection

Publications (2)

Publication Number Publication Date
IL189329A0 IL189329A0 (en) 2008-06-05
IL189329A true IL189329A (en) 2015-07-30

Family

ID=37758084

Family Applications (1)

Application Number Title Priority Date Filing Date
IL189329A IL189329A (en) 2005-08-10 2008-02-06 The vaccine against dengue fever virus infection has been used and used

Country Status (12)

Country Link
US (1) US20080193477A1 (https=)
EP (1) EP1924280A4 (https=)
JP (1) JP5227172B2 (https=)
AR (1) AR055603A1 (https=)
AU (1) AU2006280144B2 (https=)
BR (1) BRPI0614265A2 (https=)
CA (1) CA2618783A1 (https=)
IL (1) IL189329A (https=)
MY (1) MY151051A (https=)
NO (1) NO20081127L (https=)
TW (1) TW200740458A (https=)
WO (1) WO2007021672A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
AU2010256845B2 (en) * 2009-06-01 2016-09-22 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
BRPI0904020B8 (pt) 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
US9821050B2 (en) 2012-04-02 2017-11-21 The University Of North Carolina At Chapel Hill Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions
AU2013295016A1 (en) 2012-07-24 2015-01-29 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
SG10201912291YA (en) 2012-07-24 2020-02-27 Sanofi Pasteur Vaccine compositions
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
US9878031B2 (en) 2012-12-14 2018-01-30 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
EP2968516B1 (en) 2013-03-15 2022-01-12 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
KR20160119806A (ko) * 2014-02-11 2016-10-14 메사추세츠 인스티튜트 오브 테크놀로지 신규한 온전한 범위의 항-뎅기 항체
DK3197487T3 (da) 2014-09-26 2022-09-05 Seqirus Uk Ltd Vaccination af immunsvækkede individer
GB201704126D0 (en) * 2017-03-15 2017-04-26 Blom Nihlén Kim Andrea Vaccine
WO2018183429A1 (en) 2017-03-30 2018-10-04 Merck Sharp & Dohme Corp. Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids
WO2019069130A1 (en) 2017-10-05 2019-04-11 Sanofi Pasteur COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE
EP3846849A1 (en) 2018-09-05 2021-07-14 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
BR112022001476A2 (pt) 2019-08-16 2023-10-03 Takeda Vaccines Inc Uso de uma vacina contra hepatite a e uma composição de vacina contra dengue ou uma dose unitária de uma composição de vacina contra dengue, combinação de vacina e kit
BR112022015710A2 (pt) 2020-02-27 2022-09-27 Takeda Vaccines Inc Método para remover dna de célula hospedeira a partir da preparação de vírus
WO2023147342A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
US20250177511A1 (en) 2022-02-15 2025-06-05 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
US20250342705A1 (en) 2022-05-04 2025-11-06 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
WO2024108087A1 (en) 2022-11-18 2024-05-23 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
EP4626574A1 (en) 2022-11-29 2025-10-08 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US6676936B1 (en) * 1988-07-14 2004-01-13 The United States Of America As Represented By The Department Of Health And Human Services. Chimeric and/or growth-restricted flaviviruses
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
AU1813901A (en) * 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
US6966281B1 (en) * 2004-05-05 2005-11-22 Hale James R Internal combustion device and methods of use
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Also Published As

Publication number Publication date
EP1924280A4 (en) 2008-12-10
AR055603A1 (es) 2007-08-29
IL189329A0 (en) 2008-06-05
EP1924280A2 (en) 2008-05-28
MY151051A (en) 2014-03-31
TW200740458A (en) 2007-11-01
WO2007021672A2 (en) 2007-02-22
JP2009504654A (ja) 2009-02-05
WO2007021672A3 (en) 2007-11-22
US20080193477A1 (en) 2008-08-14
BRPI0614265A2 (pt) 2011-03-22
JP5227172B2 (ja) 2013-07-03
NO20081127L (no) 2008-05-07
AU2006280144B2 (en) 2012-06-14
AU2006280144A1 (en) 2007-02-22
CA2618783A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
IL189329A (en) The vaccine against dengue fever virus infection has been used and used
PL2281830T3 (pl) Szczepionka przeciw wirusowi ospy wietrznej i półpaśca
PL1859004T3 (pl) Środki sieciujące kompozycję opracowania odwiertu oraz ich zastosowania
PL1971366T3 (pl) Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie
IL191759A (en) Ganaxolone formulations and methods for the making and use thereof
LT1951272T (lt) Lactobacillus panaudojimas virusinių infekcijų gydymui
IL188520A0 (en) N-(arylalkyl)-1h-pyrrolopyridine-2-carboxamide derivatives preparation and use thereof
ZA200711105B (en) Novel physiological substance nesfatin substance relevant thereto, and use of the substances
IL186325A0 (en) Tizanidine compositions and methods of treatment using the compositions
ZA200800438B (en) N-(heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and use thereof
IL190519A0 (en) 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof
ZA200800412B (en) Substituted cyclic compound, its preparation process and its medical use
LT1858481T (lt) Oftalmologinės kompozicijos ir jų panaudojimas
PL2215908T3 (pl) 2-alkilo-cykloalk(en)ylo-karboksamidy i ich zastosowanie jako fungicydów
DE602006018019D1 (de) Pfropfcopolymer enthaltende abweisende zusammensetzung, pfropfcopolymer und herstellungsverfahren dafür
DE602006006861D1 (de) Herstellung von polytrimethylenetherglykol und copolymeren davon
DE602006006710D1 (de) Herstellung von polytrimethylenetherglykol und copolymeren davon
ATE398462T1 (de) Impfverfahren gegen testikuläre bvdv-infektion
DK1812072T3 (da) Benzothiazol-præparat og anvendelse deraf
IL186307A0 (en) Human glp-1 mimetibodies, compositions, methods and uses
IL186277A0 (en) Dnt-maleate and methods of preparation thereof
ZA200802176B (en) Vaccination against dengue virus infection
ZA200710950B (en) Lawsonia vaccine and methods of use thereof
GB0504333D0 (en) Treatment of cytokine dysregulation
EP1833989A4 (en) VIRUS PREPARATIONS AND METHODS

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees